Mostrar registro simples

dc.contributor.authorMaia, Carlos Renato Moreirapt_BR
dc.contributor.authorStella, Steffan Frosipt_BR
dc.contributor.authorMattos, Paulopt_BR
dc.contributor.authorCruz, Luciane Nascimentopt_BR
dc.contributor.authorPolanczyk, Guilherme Vanonipt_BR
dc.contributor.authorRohde, Luis Augusto Paimpt_BR
dc.contributor.authorPolanczyk, Carisi Annept_BR
dc.date.accessioned2016-08-24T02:16:10Zpt_BR
dc.date.issued2015pt_BR
dc.identifier.issn1516-4446pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/147593pt_BR
dc.description.abstractObjective: To estimate the economic consequences of the current Brazilian government policy for attention-deficit/hyperactivity disorder (ADHD) treatment and how much the country would save if treatment with immediate-release methylphenidate (MPH-IR), as suggested by the World Health Organization (WHO), was offered to patients with ADHD. Method: Based on conservative previous analyses, we assumed that 257,662 patients aged 5 to 19 years are not receiving ADHD treatment in Brazil. We estimated the direct costs and savings of treating and not treating ADHD on the basis of the following data: a) spending on ADHD patients directly attributable to grade retention and emergency department visits; and b) savings due to impact of ADHD treatment on these outcomes. Results: Considering outcomes for which data on the impact of MPH-IR treatment are available, Brazil is probably wasting approximately R$ 1.841 billion/year on the direct consequences of not treating ADHD in this age range alone. On the other hand, treating ADHD in accordance with WHO recommendations would save approximately R$ 1.163 billion/year. Conclusions: By increasing investments on MPH-IR treatment for ADHD to around R$ 377 million/ year, the country would save approximately 3.1 times more than is currently spent on the consequences of not treating ADHD in patients aged 5 to 19 years.en
dc.format.mimetypeapplication/pdf
dc.language.isoporpt_BR
dc.relation.ispartofRevista brasileira de psiquiatria (1999). São Paulo. Vol. 37, n. 1 (jan./mar. 2015), p. 67–70pt_BR
dc.rightsOpen Accessen
dc.subjectAttention-deficit/hyperactivity disorderen
dc.subjectTranstorno do déficit de atenção com hiperatividadept_BR
dc.subjectAnálise custo-eficiênciapt_BR
dc.subjectSocial and political issuesen
dc.subjectCosts and cost analysisen
dc.subjectChild psychiatryen
dc.subjectCentral nervous system stimulantsen
dc.titleThe Brazilian policy of withholding treatment for ADHD is probably increasing health and social costspt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000998345pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples